Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis

Cytokine

Volumn 89, Issue , 2017, Pages 34-44

  Qian, Xin ^a   Chen, Hankui ^b   Wu, Xiaofeng ^a   Hu, Ling ^c   Huang, Qi ^d   Jin, Yang ^d  

^a HUBEI UNIVERSITY OF MEDICINE   (China)

^b RUSH UNIVERSITY   (United States)

^c WUHAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Angiogenesis; Cytokine; Interleukin (IL) 17; Tumor immunity; Tumorigenesis

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 6; LYMPHOCYTE ANTIGEN RECEPTOR;

ADAPTIVE IMMUNITY; ADENOCARCINOMA; APOPTOSIS; AUTOIMMUNE DISEASE; BLADDER TUMOR; BREAST TUMOR; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CERVICAL ADENOCARCINOMA; CHRONIC LYMPHATIC LEUKEMIA; COLON TUMOR; COLORECTAL TUMOR; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FIBROSARCOMA; HUMAN; IMMUNE EVASION; INNATE IMMUNITY; INTESTINE TUMOR; LIVER CELL CARCINOMA; LYMPHOCYTE ACTIVATION; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NATURAL KILLER CELL; NEUTROPHIL CHEMOTAXIS; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; CELLULAR IMMUNITY; IMMUNOLOGY; PATHOLOGY; TH17 CELL;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-17; KILLER CELLS, NATURAL; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; TH17 CELLS; TUMOR MICROENVIRONMENT;

EID: 84957900677     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.09.011     Document Type: Review

References (113)

1. [1] Coussens, L.M., Werb, Z., Inflammation and cancer. Nature 420 (2002), 860–867.
2. [2] Shabgah, A.G., Fattahi, E., Shahneh, F.Z., Interleukin-17 in human inflammatory diseases. Postepy Dermatol. Alergol. 31 (2014), 256–261.
3. [3] Rouvier, E., Luciani, M.F., Mattei, M.G., Denizot, F., Golstein, P., CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J. Immunol. 150 (1993), 5445–5456.
4. [4] Yao, Z., Painter, S.L., Fanslow, W.C., Ulrich, D., Macduff, B.M., Spriggs, M.K., et al. Human IL-17: a novel cytokine derived from T cells. J. Immunol. 155 (1995), 5483–5486.
5. [5] Fossiez, F., Djossou, O., Chomarat, P., Flores-Romo, L., Ait-Yahia, S., Maat, C., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183 (1996), 2593–2603.
6. [6] Zhu, X., Mulcahy, L.A., Mohammed, R.A., Lee, A.H., Franks, H.A., Kilpatrick, L., et al. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res., 10, 2008, R95.
7. [7] Vykhovanets, E.V., Maclennan, G.T., Vykhovanets, O.V., Gupta, S., IL-17 Expression by macrophages is associated with proliferative inflammatory atrophy lesions in prostate cancer patients. Int. J. Clin. Exp. Pathol. 4 (2011), 552–565.
8. + cancer stem-like cells in ovarian cancer. Oncogene 34 (2015), 165–176.
9. [9] Korn, T., Bettelli, E., Oukka, M., Kuchroo, V.K., IL-17 and Th17 Cells. Annu. Rev. Immunol. 27 (2009), 485–517.
10. [10] Coffelt, S.B., Kersten, K., Doornebal, C.W., Weiden, J., Vrijland, K., Hau, C.S., et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature, 2015.
11. −NKT cell population. Proc. Natl. Acad. Sci. U.S.A. 105 (2008), 11287–11292.
12. [12] Rachitskaya, A.V., Hansen, A.M., Horai, R., Li, Z., Villasmil, R., Luger, D., et al. Cutting edge: NKT cells constitutively express IL-23 receptor and RORγt and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J. Immunol. 180 (2008), 5167–5171.
13. + T cells in nasopharyngeal carcinoma. J. Transl. Med., 9, 2011, 189.
14. [14] Garcia-Hernandez Mde, L., Hamada, H., Reome, J.B., Misra, S.K., Tighe, M.P., Dutton, R.W., Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J. Immunol. 184 (2010), 4215–4227.
15. + T cells in hepatocellular carcinoma patients. J. Immunol. 185 (2010), 1544–1549.
16. [16] Zhuang, Y., Peng, L.S., Zhao, Y.L., Shi, Y., Mao, X.H., Chen, W., et al. CD8(+) T cells that produce interleukin-17 regulate myeloid-derived suppressor cells and are associated with survival time of patients with gastric cancer. Gastroenterology, 143(951–62), 2012, e8.
17. + T cells. Scand. J. Immunol. 74 (2011), 47–51.
18. + T cells promote development of cancer-initiating cells in colorectal cancer. J. Leukoc. Biol. 89 (2011), 85–91.
19. [19] Numasaki, M., Watanabe, M., Suzuki, T., Takahashi, H., Nakamura, A., McAllister, F., et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J. Immunol. 175 (2005), 6177–6189.
20. [20] Punt, S., Fleuren, G.J., Kritikou, E., Lubberts, E., Trimbos, J.B., Jordanova, E.S., et al. Angels and demons: Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer. Oncoimmunology, 4, 2015, e984539.
21. [21] Liu, X., Jin, H., Zhang, G., Lin, X., Chen, C., Sun, J., et al. Intratumor IL-17-positive mast cells are the major source of the IL-17 that is predictive of survival in gastric cancer patients. PLoS ONE, 9, 2014, e106834.
22. [22] Wang, B., Li, L., Liao, Y., Li, J., Yu, X., Zhang, Y., et al. Mast cells expressing interleukin 17 in the muscularis propria predict a favorable prognosis in esophageal squamous cell carcinoma. Cancer Immunol. Immunother. 62 (2013), 1575–1585.
23. [23] Yang, Z., Zhang, B., Li, D., Lv, M., Huang, C., Shen, G.X., et al. Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. PLoS ONE, 5, 2010, e8922.
24. [24] Takatori, H., Kanno, Y., Watford, W.T., Tato, C.M., Weiss, G., Ivanov, I.I., et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J. Exp. Med. 206 (2009), 35–41.
25. [25] Wakita, D., Sumida, K., Iwakura, Y., Nishikawa, H., Ohkuri, T., Chamoto, K., et al. Tumor-infiltrating IL-17-producing γδ T cells support the progression of tumor by promoting angiogenesis. Eur. J. Immunol. 40 (2010), 1927–1937.
26. [26] Takeuchi, A., Dejima, T., Yamada, H., Shibata, K., Nakamura, R., Eto, M., et al. IL-17 production by γδ T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guerin treatment against bladder cancer. Eur. J. Immunol. 41 (2011), 246–251.
27. [27] Ma, Y., Aymeric, L., Locher, C., Mattarollo, S.R., Delahaye, N.F., Pereira, P., et al. Contribution of IL-17-producing γδ T cells to the efficacy of anticancer chemotherapy. J. Exp. Med. 208 (2011), 491–503.
28. [28] Ma, S., Cheng, Q., Cai, Y., Gong, H., Wu, Y., Yu, X., et al. IL-17A produced by γδ T cells promotes tumor growth in hepatocellular carcinoma. Cancer Res. 74 (2014), 1969–1982.
29. [29] Park, E., Park, Y.S., Park, D.R., Jung, S.A., Han, D.S., Jang, B.I., et al. Cytokine expression of microscopic colitis including interleukin-17. Gut Liver, 2014.
30. [30] Steiner, G.E., Newman, M.E., Paikl, D., Stix, U., Memaran-Dagda, N., Lee, C., et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 56 (2003), 171–182.
31. [31] Sun, X., Guo, L., Wang, H., Yu, H., Wang, J., Meng, X., et al. The presence of tumor-infiltrating IL-17-producing cells in juvenile nasopharyngeal angiofibroma tumor microenvironment is a poor prognostic factor. Am. J. Otolaryngol. 35 (2014), 582–588.
32. [32] Wagsater, D., Lofgren, S., Hugander, A., Dimberg, J., Expression of interleukin-17 in human colorectal cancer. Anticancer Res. 26 (2006), 4213–4216.
33. [33] Chang, Y.H., Yu, C.W., Lai, L.C., Tsao, C.H., Ho, K.T., Yang, S.C., et al. Up-regulation of interleukin-17 expression by human papillomavirus type 16 E6 in nonsmall cell lung cancer. Cancer 116 (2010), 4800–4809.
34. [34] Lin, Y., Xu, J., Su, H., Zhong, W., Yuan, Y., Yu, Z., et al. Interleukin-17 is a favorable prognostic marker for colorectal cancer. Clin. Transl. Oncol. 17 (2015), 50–56.
35. [35] Haudenschild, D., Moseley, T., Rose, L., Reddi, A.H., Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer. J. Biol. Chem. 277 (2002), 4309–4316.
36. [36] Yao, Z., Spriggs, M.K., Derry, J.M., Strockbine, L., Park, L.S., VandenBos, T., et al. Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine 9 (1997), 794–800.
37. [37] Gaffen, S.L., An overview of IL-17 function and signaling. Cytokine 43 (2008), 402–407.
38. [38] Zhang, B., Rong, G., Wei, H., Zhang, M., Bi, J., Ma, L., et al. The prevalence of Th17 cells in patients with gastric cancer. Biochem. Biophys. Res. Commun. 374 (2008), 533–537.
39. + Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer. Oncol. Rep. 25 (2011), 1271–1277.
40. [40] Zhou, P., Sha, H., Zhu, J., The role of T-helper 17 (Th17) cells in patients with medulloblastoma. J. Int. Med. Res. 38 (2010), 611–619.
41. [41] Kato, T., Furumoto, H., Ogura, T., Onishi, Y., Irahara, M., Yamano, S., et al. Expression of IL-17 mRNA in ovarian cancer. Biochem. Biophys. Res. Commun. 282 (2001), 735–738.
42. [42] Liu, J., Duan, Y., Cheng, X., Chen, X., Xie, W., Long, H., et al. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem. Biophys. Res. Commun. 407 (2011), 348–354.
43. [43] Chen, X., Wan, J., Liu, J., Xie, W., Diao, X., Xu, J., et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 69 (2010), 348–354.
44. [44] Ciree, A., Michel, L., Camilleri-Broet, S., Jean Louis, F., Oster, M., Flageul, B., et al. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). Int. J. Cancer 112 (2004), 113–120.
45. [45] Nam, J.S., Terabe, M., Kang, M.J., Chae, H., Voong, N., Yang, Y.A., et al. Transforming growth factor β subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res. 68 (2008), 3915–3923.
46. [46] He, D., Li, H., Yusuf, N., Elmets, C.A., Li, J., Mountz, J.D., et al. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J. Immunol. 184 (2010), 2281–2288.
47. [47] Gu, F.M., Li, Q.L., Gao, Q., Jiang, J.H., Zhu, K., Huang, X.Y., et al. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. Mol. Cancer, 10, 2011, 150.
48. [48] Sun, Y., Pan, J., Mao, S., Jin, J., IL-17/miR-192/IL-17Rs regulatory feedback loop facilitates multiple myeloma progression. PLoS ONE, 9, 2014, e114647.
49. [49] Wang, L., Yi, T., Kortylewski, M., Pardoll, D.M., Zeng, D., Yu, H., IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 206 (2009), 1457–1464.
50. [50] Inozume, T., Hanada, K., Wang, Q.J., Yang, J.C., IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells. J. Immunother. 32 (2009), 109–117.
51. [51] Waugh, D.J., Wilson, C., The interleukin-8 pathway in cancer. Clin. Cancer Res. 14 (2008), 6735–6741.
52. [52] He, D., Li, H., Yusuf, N., Elmets, C.A., Athar, M., Katiyar, S.K., et al. IL-17 mediated inflammation promotes tumor growth and progression in the skin. PLoS ONE, 7, 2012, e32126.
53. [53] Chang, S.H., Mirabolfathinejad, S.G., Katta, H., Cumpian, A.M., Gong, L., Caetano, M.S., et al. T helper 17 cells play a critical pathogenic role in lung cancer. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), 5664–5669.
54. [54] Hayata, K., Iwahashi, M., Ojima, T., Katsuda, M., Iida, T., Nakamori, M., et al. Inhibition of IL-17A in tumor microenvironment augments cytotoxicity of tumor-infiltrating lymphocytes in tumor-bearing mice. PLoS ONE, 8, 2013, e53131.
55. [55] Jovanovic, D.V., Di Battista, J.A., Martel-Pelletier, J., Jolicoeur, F.C., He, Y., Zhang, M., et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-β and TNF-α, by human macrophages. J. Immunol. 160 (1998), 3513–3521.
56. [56] Elkabets, M., Ribeiro, V.S., Dinarello, C.A., Ostrand-Rosenberg, S., Di Santo, J.P., Apte, R.N., et al. IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur. J. Immunol. 40 (2010), 3347–3357.
57. [57] Tartour, E., Fossiez, F., Joyeux, I., Galinha, A., Gey, A., Claret, E., et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res. 59 (1999), 3698–3704.
58. [58] Li, Q., Liu, L., Zhang, Q., Liu, S., Ge, D., You, Z., Interleukin-17 indirectly promotes M2 macrophage differentiation through stimulation of COX-2/PGE2 pathway in the cancer cells. Cancer Res. Treat. 46 (2014), 297–306.
59. [59] Chae, W.J., Gibson, T.F., Zelterman, D., Hao, L., Henegariu, O., Bothwell, A.L., Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 5540–5544.
60. [60] Kryczek, I., Wei, S., Zou, L., Altuwaijri, S., Szeliga, W., Kolls, J., et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol. 178 (2007), 6730–6733.
61. [61] Toh, M.L., Kawashima, M., Zrioual, S., Hot, A., Miossec, P., IL-17 inhibits human Th1 differentiation through IL-12Rβ2 downregulation. Cytokine 48 (2009), 226–230.
62. [62] Cavallaro, U., Christofori, G., Molecular mechanisms of tumor angiogenesis and tumor progression. J. Neurooncol. 50 (2000), 63–70.
63. [63] Hirahara, N., Nio, Y., Sasaki, S., Minari, Y., Takamura, M., Iguchi, C., et al. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. Oncology 61 (2001), 79–89.
64. [64] Numasaki, M., Fukushi, J., Ono, M., Narula, S.K., Zavodny, P.J., Kudo, T., et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 101 (2003), 2620–2627.
65. [65] Benchetrit, F., Ciree, A., Vives, V., Warnier, G., Gey, A., Sautes-Fridman, C., et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 99 (2002), 2114–2121.
66. [66] Kryczek, I., Wei, S., Szeliga, W., Vatan, L., Zou, W., Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114 (2009), 357–359.
67. [67] Honorati, M.C., Cattini, L., Facchini, A., Possible prognostic role of IL-17R in osteosarcoma. J. Cancer Res. Clin. Oncol. 133 (2007), 1017–1021.
68. [68] Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92 (1998), 4150–4166.
69. [69] Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L., Carbone, D.P., et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hemopoietic progenitor cells. J. Immunol. 160 (1998), 1224–1232.
70. [70] Chen, X., Xie, Q., Cheng, X., Diao, X., Cheng, Y., Liu, J., et al. Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells. Cancer Sci. 101 (2010), 2384–2390.
71. [71] Qiu, L., He, D., Fan, X., Li, Z., Liao, C., Zhu, Y., et al. The expression of interleukin (IL)-17 and IL-17 receptor and MMP-9 in human pituitary adenomas. Pituitary 14 (2011), 266–275.
72. [72] Li, J., Lau, G.K., Chen, L., Dong, S.S., Lan, H.Y., Huang, X.R., et al. Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PLoS ONE, 6, 2011, e21816.
73. [73] Tanimura, Y., Kokuryo, T., Tsunoda, N., Yamazaki, Y., Oda, K., Nimura, Y., et al. Tumor necrosis factor α promotes invasiveness of cholangiocarcinoma cells via its receptor, TNFR2. Cancer Lett. 219 (2005), 205–213.
74. [74] Bar-Eli, M., Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 67 (1999), 12–18.
75. [75] Rosette, C., Roth, R.B., Oeth, P., Braun, A., Kammerer, S., Ekblom, J., et al. Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis 26 (2005), 943–950.
76. [76] Roland, C.L., Harken, A.H., Sarr, M.G., Barnett, C.C. Jr., ICAM-1 expression determines malignant potential of cancer. Surgery 141 (2007), 705–707.
77. [77] Heerboth, S., Housman, G., Leary, M., Longacre, M., Byler, S., Lapinska, K., et al. EMT and tumor metastasis. Clin. Transl. Med., 4, 2015, 6.
78. [78] Gu, K., Li, M.M., Shen, J., Liu, F., Cao, J.Y., Jin, S., et al. Interleukin-17-induced EMT promotes lung cancer cell migration and invasion via NF-κB/ZEB1 signal pathway. Am. J. Cancer Res. 5 (2015), 1169–1179.
79. [79] Chen, J.G., Xia, J.C., Liang, X.T., Pan, K., Wang, W., Lv, L., et al. Intratumoral expression of IL-17 and its prognostic role in gastric adenocarcinoma patients. Int. J. Biol. Sci. 7 (2011), 53–60.
80. [80] Lv, L., Pan, K., Li, X.D., She, K.L., Zhao, J.J., Wang, W., et al. The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. PLoS ONE, 6, 2011, e18219.
81. [81] Lu, L., Pan, K., Zheng, H.X., Li, J.J., Qiu, H.J., Zhao, J.J., et al. IL-17A promotes immune cell recruitment in human esophageal cancers and the infiltrating dendritic cells represent a positive prognostic marker for patient survival. J. Immunother. 36 (2013), 451–458.
82. [82] Kryczek, I., Banerjee, M., Cheng, P., Vatan, L., Szeliga, W., Wei, S., et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114 (2009), 1141–1149.
83. [83] Jain, P., Javdan, M., Feger, F.K., Chiu, P.Y., Sison, C., Damle, R.N., et al. Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica 97 (2012), 599–607.
84. [84] Punt, S., van Vliet, M.E., Spaans, V.M., de Kroon, C.D., Fleuren, G.J., Gorter, A., et al. FoxP3 and IL-17 cells are correlated with improved prognosis in cervical adenocarcinoma. Cancer Immunol. Immunother., 2015.
85. [85] Hirahara, N., Nio, Y., Sasaki, S., Takamura, M., Iguchi, C., Dong, M., et al. Reduced invasiveness and metastasis of Chinese hamster ovary cells transfected with human interleukin-17 gene. Anticancer Res. 20 (2000), 3137–3142.
86. [86] Honorati, M.C., Neri, S., Cattini, L., Facchini, A., IL-17 enhances the susceptibility of U-2 OS osteosarcoma cells to NK cell lysis. Clin. Exp. Immunol. 133 (2003), 344–349.
87. [87] Fisher, D.T., Appenheimer, M.M., Evans, S.S., The two faces of IL-6 in the tumor microenvironment. Semin. Immunol. 26 (2014), 38–47.
88. [88] Fisher, D.T., Chen, Q., Skitzki, J.J., Muhitch, J.B., Zhou, L., Appenheimer, M.M., et al. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J. Clin. Invest. 121 (2011), 3846–3859.
89. [89] Saito, K., Ishikura, H., Kishimoto, T., Kawarada, Y., Yano, T., Takahashi, T., et al. Interleukin-6 produced by pancreatic carcinoma cells enhances humoral immune responses against tumor cells: a possible event in tumor regression. Int. J. Cancer 75 (1998), 284–289.
90. [90] Trinchieri, G., Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3 (2003), 133–146.
91. [91] Markiewicz, M.A., Wise, E.L., Buchwald, Z.S., Cheney, E.E., Hansen, T.H., Suri, A., et al. IL-12 enhances CTL synapse formation and induces self-reactivity. J. Immunol. 182 (2009), 1351–1361.
92. [92] Katano, M., Torisu, M., Neutrophil-mediated tumor cell destruction in cancer ascites. Cancer 50 (1982), 62–68.
93. [93] Brackett, C.M., Muhitch, J.B., Evans, S.S., Gollnick, S.O., IL-17 promotes neutrophil entry into tumor-draining lymph nodes following induction of sterile inflammation. J. Immunol. 191 (2013), 4348–4357.
94. [94] Droeser, R.A., Hirt, C., Eppenberger-Castori, S., Zlobec, I., Viehl, C.T., Frey, D.M., et al. High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favorable prognostic factor. PLoS ONE, 8, 2013, e64814.
95. [95] Caruso, R.A., Bellocco, R., Pagano, M., Bertoli, G., Rigoli, L., Inferrera, C., Prognostic value of intratumoral neutrophils in advanced gastric carcinoma in a high-risk area in northern Italy. Mod. Pathol. 15 (2002), 831–837.
96. [96] Eruslanov, E.B., Bhojnagarwala, P.S., Quatromoni, J.G., Stephen, T.L., Ranganathan, A., Deshpande, C., et al. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J. Clin. Invest. 124 (2014), 5466–5480.
97. [97] Fridlender, Z.G., Albelda, S.M., Tumor-associated neutrophils: friend or foe?. Carcinogenesis 33 (2012), 949–955.
98. [98] Heuvers, M.E., Aerts, J.G., Cornelissen, R., Groen, H., Hoogsteden, H.C., Hegmans, J.P., Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment. BMC Cancer, 12, 2012, 580.
99. [99] Fridlender, Z.G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., et al. Polarization of tumor-associated neutrophil phenotype by TGF-β: “N1” versus “N2” TAN. Cancer Cell 16 (2009), 183–194.
100. [100] Laan, M., Cui, Z.H., Hoshino, H., Lotvall, J., Sjostrand, M., Gruenert, D.C., et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J. Immunol. 162 (1999), 2347–2352.
101. [101] Witowski, J., Pawlaczyk, K., Breborowicz, A., Scheuren, A., Kuzlan-Pawlaczyk, M., Wisniewska, J., et al. IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GROα chemokine from mesothelial cells. J. Immunol. 165 (2000), 5814–5821.
102. [102] Lemos, H.P., Grespan, R., Vieira, S.M., Cunha, T.M., Verri, W.A. Jr., Fernandes, K.S., et al. Prostaglandin mediates IL-23/IL-17-induced neutrophil migration in inflammation by inhibiting IL-12 and IFNγ production. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 5954–5959.
103. [103] Pelletier, M., Maggi, L., Micheletti, A., Lazzeri, E., Tamassia, N., Costantini, C., et al. Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 115 (2010), 335–343.
104. [104] Huber, M., Heink, S., Grothe, H., Guralnik, A., Reinhard, K., Elflein, K., et al. A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity. Eur. J. Immunol. 39 (2009), 1716–1725.
105. [105] Zhu, Y., Ju, S., Chen, E., Dai, S., Li, C., Morel, P., et al. T-bet and eomesodermin are required for T cell-mediated antitumor immune responses. J. Immunol. 185 (2010), 3174–3183.
106. [106] Vanaudenaerde, B.M., Verleden, S.E., Vos, R., De Vleeschauwer, S.I., Willems-Widyastuti, A., Geenens, R., et al. Innate and adaptive interleukin-17-producing lymphocytes in chronic inflammatory lung disorders. Am. J. Respir. Crit. Care Med. 183 (2011), 977–986.
107. [107] Crowe, N.Y., Coquet, J.M., Berzins, S.P., Kyparissoudis, K., Keating, R., Pellicci, D.G., et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 202 (2005), 1279–1288.
108. [108] Yang, L., DeBusk, L.M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6 (2004), 409–421.
109. [109] Taylor, P.R., Roy, S., Leal, S.M. Jr., Sun, Y., Howell, S.J., Cobb, B.A., et al. Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, RORγt and dectin-2. Nat. Immunol. 15 (2014), 143–151.
110. [110] Song, C., Luo, L., Lei, Z., Li, B., Liang, Z., Liu, G., et al. IL-17-producing alveolar macrophages mediate allergic lung inflammation related to asthma. J. Immunol. 181 (2008), 6117–6124.
111. [111] Unutmaz, D., RORC2: the master of human Th17 cell programming. Eur. J. Immunol. 39 (2009), 1452–1455.
112. [112] Huang, Q., Fan, J., Qian, X., Lv, Z., Zhang, X., Han, J., et al. Retinoic acid-related orphan receptor C isoform 2 expression and its prognostic significance for non-small cell lung cancer. J. Cancer Res. Clin. Oncol., 2015.
113. [113] Li, Y.X., Zhang, L., Simayi, D., Zhang, N., Tao, L., Yang, L., et al. Human papillomavirus infection correlates with inflammatory Stat3 signaling activity and IL-17 level in patients with colorectal cancer. PLoS ONE, 10, 2015, e0118391.